# US 2010/0144681 A1 · Compounds for the treatment of alzheimer's disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0144681 A1
- Document ID: US20100144681A1
- Status: Published application
- Kind: A1
- Application number: 12/063,356
- Filed: 2006-08-08
- Published: 2010-06-10
- Earliest claimed: 2005-08-11
- Inventors: Klaus Fuchs; Christian Eickmeier; Niklas Heine; Stefan Peters; Cornelia Dorner-Ciossek; Sandra Handschuh; Herbert Nar; Klaus Klinder
- Web page: https://patentgrep.com/patent/US20100144681A1

## CPC

- C07C 311/08: having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 307/10: having nitrogen atoms of the sulfamide groups bound to carbon atoms of six-membered aromatic rings
- C07C 311/21: having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07D 213/40: Acylated substituent nitrogen atom
- C07D 231/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 265/10: with oxygen atoms directly attached to ring carbon atoms
- C07D 277/28: Radicals substituted by nitrogen atoms
- C07D 285/16: Thiadiazines; Hydrogenated thiadiazines
- C07D 333/20: by nitrogen atoms (nitro, nitroso radicals C07D333/12)
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07C 2601/02: with a three-membered ring
- C07C 2601/04: with a four-membered ring
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The invention relates to substituted 1,2-ethylenediamines of general formula (I), wherein the radicals R1-R13, A, B, L and i are as defined in the description and the claims. The invention also relates to the use thereof for treating Alzheimer's disease (AD) and similar diseases.

## Claims

### Claim 1

Compounds of general formula (I)
wherein
A denotes aryl or heteroaryl,
wherein the group A, besides the groups L, may optionally be substituted by one or more fluorine atoms,
L in each case independently of one another denote hydrogen, fluorine, chlorine, bromine, iodine, hydroxy, carboxy, formyl, cyano, nitro, F3C, HF2C, FH2C, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C1-6-alkyl-S, C1-6-alkyl-S-C1-3-alkyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C2-6-alkenyl, C3-7-cycloalkyl-C2-6-alkynyl, C3-7-cycloalkenyl, C3-7-cycloalkenyl-C1-6-alkyl, C3-7-cycloalkenyl-C2-6-alkenyl, C3-7-cycloalkenyl-C2-6-alkynyl, heterocyclyl, heterocyclyl-C1-6-alkyl, heterocyclyl-C2-6-alkenyl, heterocyclyl-C2-6-alkynyl, aryl, aryl-C1-6-alkyl, aryl-C2-6-alkenyl, aryl-C2-6-alkynyl, aryl-C3-7-cycloalkyl, heteroaryl, heteroaryl-C1-6-alkyl, heteroaryl-C2-6-alkenyl, heteroaryl-C2-6-alkynyl, heteroaryl-C3-7-cycloalkyl, R13—O, R13—O—C1-3-alkyl, (R12)2N, (R12)2N—CO, R12-CO—(R12)N, (R12)2N—CO—(R12)N, R12—SO2—(R12)2N—SO2 or C1-6-alkyl-SO2,
wherein the above mentioned groups may optionally be substituted independently of one another by one or more groups selected from among fluorine, chlorine, bromine, iodine, hydroxy, oxo, carboxy, formyl, cyano, nitro, F3C, HF2C, FH2C, hydroxy-C1-6-alkyl, C1-3-alkyl, C1-6-alkoxy, (R12)2N, (R12)2N—C1-3-alkyl, (R12)2N—CO— and HOSO2—,
i denotes 0, 1, 2 or 3,
B denotes a C1-4-alkylene bridge,
while the C1-4-alkylene bridge may optionally be substituted by one or more groups selected from among fluorine, chlorine, bromine, iodine, hydroxy, oxo, carboxy, cyano, nitro, F3C, HF2C, FH2C, C1-4-alkyl, C1-6-alkyl-S—C1-3-alkyl, C3-7-cycloalkyl, heterocyclyl, heterocyclyl-C1-3-alkyl, aryl, aryl-C1-3-alkyl, aryl-C3-7-cycloalkyl, heteroaryl, heteroaryl-C1-3-alkyl, heteroaryl-C3-7-cycloalkyl, R13—O, (R12)2N—SO2, (R12)2N, (R12)2N—C1-3-alkyl, (R12)2N—CO, R12—SO2, R12—CO—(R12)N, R12—SO2(R12)N, (R12)2N—SO2, R12—CO— and R1213 SO—, and
wherein two C1-4-alkyl groups bound to the same carbon atom of the C1-4-alkylene bridge may be joined together, forming a C3-7-cycloalkyl group, and wherein the above mentioned C1-4-alkyl groups and the C3-7-cycloalkyl group formed from the C1-4-alkyl groups may optionally be substituted independently of one another by one or more groups selected from among fluorine, chlorine, bromine, iodine, hydroxy, oxo, carboxy, formyl, cyano, nitro, F3C, C1-3-alkyl, C1-3alkoxy, R13—O—C1-3-alkyl, R12—CO(R12)N, R12—SO2(R12)N, (R12)2N, (R12)2N—C1-3-alkyl, (R12)2N—CO, (R12)2N—SO2— and HOSO2—,
R1 denotes hydrogen, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-6-alkyl, C3-7-cycloalkyl-C2-6-alkenyl, C3-7-cycloalkyl-C2-6-alkynyl, C3-7-cycloalkenyl, C3-7-cycloalkenyl-C1-6-alkyl, C3-7-cycloalkenyl-C2-6-alkenyl, C3-7-cycloalkenyl-C2-6-alkynyl, heterocyclyl, heterocyclyl-C1-6-alkyl, heterocyclyl-C2-6-alkenyl, heterocyclyl-C2-6-alkynyl, aryl, aryl-C1-6-alkyl, aryl-C2-6-alkenyl, aryl-C2-6-alkynyl, aryl-C3-7-cycloalkyl, heteroaryl, heteroaryl-C1-6-alkyl, heteroaryl-C2-6-alkenyl, heteroaryl-C2-6-alkynyl or heteroaryl-C3-7-cycloalkyl,
wherein the above mentioned groups may optionally be substituted independently of one another by one or more groups selected from among fluorine, chlorine, bromine, iodine, hydroxy, oxo, carboxy, formyl, cyano, nitro, F3C, C1-3-alkyl, C1-3-alkoxy, hydroxy-C1-6-alkyl, (R12)2N, (R12)2N—C1-3-alkyl, (R12)2N—CO, (R12)2N—SO2, R12—CO—(R12)N, R12—SO2(R12)N— and HOSO2—,
R2 denotes C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C1-6-alkoxy-C1-3-alkyl, C1-6-alkyl-S—C1-3-alkyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C2-3-alkenyl, C3-7-cycloalkyl-C2-3-alkynyl, C3-7-cycloalkenyl, C3-7-cycloalkenyl-C1-3-alkyl, C3-7-cycloalkenyl-C2-3-alkenyl, C3-7-cycloalkenyl-C2-3-alkynyl, heterocyclyl, heterocyclyl-C1-3-alkyl, heterocyclyl-C2-3-alkenyl, heterocyclyl-C2-3-alkynyl, aryl, aryl-C1-3-alkyl, aryl-C2-3-alkenyl, aryl-C2-3-alkynyl, aryl-C3-7-cycloalkyl, heteroaryl, heteroaryl-C1-3-alkyl, heteroaryl-C2-3-alkenyl, heteroaryl-C2-3-alkynyl or heteroaryl-C3-7-cycloalkyl,
wherein the above mentioned groups may optionally be substituted independently of one another by one or more groups selected from among fluorine, chlorine, bromine, iodine, F3C, HF2C, FH2C— hydroxy, oxo, carboxy, formyl, cyano, nitro, (R12)2N, (R12)2N—C1-3-alkyl, HOSO2, C1-3-alkyl, C1-6-alkyl-S—C1-3-alkyl, (R12)2N—SO2, R12—CO—(R12)N, R12—SO2(R12)N, (R12)2N—C1-3-alkyl, (R12)2N—CO, R13—O— and R13—O—C1-3-alkyl-,
R3, R4 in each case independently of one another denote hydrogen, C1-6-alkyl, fluorine, F3C, HF2C or FH2C,
R5 denotes hydrogen, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-4-alkyl, C3-7-cycloalkyl-C2-4-alkenyl, C3-7-cycloalkyl-C2-4-alkynyl, C3-7-cycloalkenyl, C3-7-cycloalkenyl-C1-4-alkyl, C3-7-cycloalkenyl-C2-4-alkenyl, C3-7-cycloalkenyl-C2-4-alkynyl, heterocyclyl, heterocyclyl-C1-4-alkyl, heterocyclyl-C2-4-alkenyl, heterocyclyl-C2-4-alkynyl, aryl, aryl-C1-4-alkyl, aryl-C2-4-alkenyl, aryl-C2-4-alkynyl, aryl-C3-7-cycloalkyl, heteroaryl, heteroaryl-C1-4-alkyl, heteroaryl-C2-4-alkenyl, heteroaryl-C2-4-alkynyl or heteroaryl-C3-7-cycloalkyl,
wherein the above mentioned groups may optionally be substituted independently of one another by one or more groups selected from among fluorine, chlorine, bromine, iodine, hydroxy, oxo, carboxy, formyl, cyano, nitro, C1-3-alkyl, C1-6-alkoxy, C1-3-alkyl-S, aryl, heteroaryl, heteroaryl-C1-3-alkyl, aryl-C1-6-alkyl, R12—CO—(R12)N, R12—SO2(R12)N—(R12)2N—SO2, (R12)2N, (R12)2N—C1-3-alkyl, (R12)2N—CO— and HOSO2—,
R6 denotes C2-6-alkenyl, C2-6-alkynyl, C3-7-cycloalkyl-C2-4-alkenyl, C3-7-cycloalkyl-C2-4-alkynyl, C3-7-cycloalkenyl, C3-7-cycloalkenyl-C1-6-alkyl, C3-7-cycloalkenyl-C2-6-alkenyl, C3-7-cycloalkenyl-C2-6-alkynyl, heterocyclyl, heterocyclyl-C1-3-alkyl, heterocyclyl-C2-4-alkenyl, heterocyclyl-C2-4-alkynyl, aryl-C2-4-alkyl-(R12)2N-aryl, (R12)2N-aryl-C1-3-alkyl, aryl-C2-4-alkenyl, aryl-C2-4-alkynyl, aryl-C3-7-cycloalkyl, heteroaryl, heteroaryl-C1-3-alkyl, heteroaryl-C2-4-alkenyl, heteroaryl-C2-4-alkynyl or heteroaryl-C3-7-cycloalkyl,
wherein the above mentioned groups may optionally be substituted independently of one another by one or more groups selected from among fluorine, chlorine, bromine, iodine, hydroxy, oxo, carboxy, formyl, cyano, nitro, C1-3-alkyl, C3-7-cycloalkyl, heterocyclyl, heterocyclyl-C1-3-alkyl, R13—O, R13—O—C1-3-alkyl, aryl, heteroaryl, heteroaryl-C1-3-alkyl, aryl-C1-6-alkyl, (R12)2N, (R12)2N—C1-3-alkyl, (R12)2N—CO, R12—CO—(R12)N, (R12)2N—CO—N(R12), (R12)2N—SO2, R12—SO2—(R12)N— and HOSO 2—,
R7 denotes hydrogen, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C1-6-alkoxy-C1-3-alkyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-3-alkyl, heterocyclyl-C1-3-alkyl, aryl, aryl-C1-3-alkyl, heteroaryl or heteroaryl-C1-3-alkyl,
wherein the above mentioned groups may optionally be substituted independently of one another by one or more groups selected from among fluorine, chlorine, bromine, iodine, cyano, hydroxy, C1-3-alkyl, C1-6-alkoxy- and (R12)2N—,
R8 denotes hydrogen, fluorine, chlorine, bromine, iodine, cyano, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-6-alkyl, C3-7-cycloalkyl-C2-6-alkenyl, C3-7-cycloalkyl-C2-6-alkynyl, C3-7-cycloalkenyl, C3-7-cycloalkenyl-C1-6-alkyl, C3-7-cycloalkenyl-C2-6-alkenyl, C3-7-cycloalkenyl-C2-6-alkynyl, heterocyclyl, heterocyclyl-C1-6-alkyl, heterocyclyl-C2-6-alkenyl, heterocyclyl-C2-6-alkynyl, aryl, aryl-C1-6-alkyl, aryl-C2-6-alkenyl, aryl-C2-6-alkynyl, aryl-C3-7-cycloalkyl, heteroaryl, heteroaryl-C1-6-alkyl, heteroaryl-C2-6-alkenyl, heteroaryl-C2-6-alkynyl, heteroaryl-C3-7-cycloalkyl, R13—O, R13—O—C1-3-alkyl, R10—SO2—(R11)N or R10—CO—(R11)N,
wherein the above mentioned groups may optionally be substituted independently of one another by one or more groups selected from among C1-6-alkyl, fluorine, chlorine, bromine, hydroxy, oxo, carboxy, formyl, cyano, nitro, C2-6-alkenyl, C2-6-alkynyl, C1-6-alkyl-S, C1-6-alkyl-S—C1-3-alkyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-6-alkyl, aryl, aryl-C1-6-alkyl, heterocyclyl, heterocyclyl-C1-6-alkyl, heteroaryl, heteroaryl-C1-6-alkyl, R13_O, R13—O—CO, R13—CO, R13—O—CO—(R12)N, (R12)2N—CO—O, R13—O—C1-3-alkyl, (R12)2N, (R12)2N—CO, R12—CO—(R12)N, (R12)2N—CO—(R12)N, (R12)2N—SO2, (R12)2N—SO2—(R12)N, R12—SO2, F3C, HF2C, FH2C, F3C—O, HF2C—O, FH2C—O— and R12—SO2—(R12)N—,
R9 in each case independently of one another denote hydrogen, fluorine, chlorine, bromine, iodine, C1-3-alkyl, R13—O or (R12)2N,
while the above mentioned C1-3-alkyl group may optionally be substituted by one or more fluorine atoms,
R10 denotes C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-4-alkyl, C3-7-cycloalkyl-C2-4-alkenyl, C3-7-cycloalkyl-C2-4-alkylyl, C3-7-cycloalkenyl, C3-7-cycloalkenyl-C1-4-alkyl, C3-7-cycloalkenyl-C2-4-alkenyl, C3-7-cycloalkenyl-C2-4-alkynyl, heterocyclyl, heterocyclyl-C1-4-alkyl, heterocyclyl-C2-4-alkenyl, heterocyclyl-C2-4-alkynyl, aryl, aryl-C1-4-alkyl, aryl-C2-4-alkenyl, aryl-C2-4-alkynyl, aryl-C3-7-cycloalkyl, heteroaryl, heteroaryl-C1-4-alkyl, heteroaryl-C2-4-alkenyl, heteroaryl-C2-4-alkynyl, heteroaryl-C3-7-cycloalkyl or (R12)2N,
wherein the above mentioned groups may optionally be substituted independently of one another by one or more groups selected from among fluorine, chlorine, bromine, hydroxy, oxo, carboxy, formyl, cyano, nitro, C1-3-alkyl, heterocyclyl, heterocyclyl-C1-3-alkyl, R13—O, R13—O—C1-3-alkyl, R12—CO(R12)N, R12—SO2(R12)N, (R12)2N—SO2, R12—SO2, R12—SO, R12_S, (R12)2N, (R12)2N—C1-3-alkyl- and (R12)2N—CO—,
R11 denotes hydrogen, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-3-alkyl, heterocyclyl, heterocyclyl-C1-3-alkyl, heterocyclyl-C2-3-alkenyl, heterocyclyl-C2-3-alkynyl, aryl, aryl-C1-3-alkyl, heteroaryl, heteroaryl-C1-3-alkyl, heteroaryl-C2-3-alkenyl or heteroaryl-C2-3-alkynyl,
wherein the above mentioned groups may optionally be substituted independently of one another by one or more groups selected from among fluorine, chlorine, bromine, hydroxy, oxo, carboxy, formyl, cyano, nitro, C1-3-alkyl, heterocyclyl, heterocyclyl-C1-3-alkyl, R13—O, R13—O—C1-3alkyl, (R12)2N—SO2, R12—SO2, R12—SO, R12—S, (R12)2N, (R12)2N—C1-3-alkyl- and R12CO—,
or
R10 and R11 together form a C2-6-alkylene bridge, so that a heterocyclic ring is formed with the inclusion of the nitrogen atom linked to R11 and the SO2— or CO— group linked to R10,
wherein one or two —CH2 groups of the C2-6-alkylene bridge may be replaced independently of one another by O, S, SO, SO2 or —N(R12)— such that in each case two O or S atoms or an O and an S atom are not directly connected to one another, and
wherein the C atoms of the above mentioned C2-6-alkylene bridge may optionally be substituted by one or more groups selected from among fluorine, chlorine, bromine, hydroxy, carboxy, formyl, cyano, F3C, C1-6-alkyl, C1-6-alkoxy, oxo and nitro,
R12 in each case independently of one another denote hydrogen, C1-6-alkyl, C1-6-alkoxy, C1-3-alkyl, C3-6-cycloalkyl, C3-6-cycloalkyl-C1-3-alkyl, heterocyclyl, heterocyclyl-C1-3-alkyl, aryl, aryl-C1-3-alkyl, heteroaryl or heteroaryl-C1-3-alkyl, wherein
two C1-6-alkyl groups bound to the same nitrogen atom may together form a C2-6-alkylene bridge, so that a heterocyclic ring is formed with the inclusion of the nitrogen atoms linked to the groups R12,
while a —CH2 group of the C2-6-alkylene bridge may be replaced by O, S or —N(R13)—, and
wherein the above mentioned groups and the heterocyclic ring may optionally be substituted independently of one another by one or more groups selected from among fluorine, chlorine, bromine, iodine, hydroxy, oxo, carboxy, formyl, cyano, nitro, C1-3-alkyl, hydroxy-C1-3-alkyl, C1-3-alkoxy, (R13)2N—CO or (R13)2N—, and
R13 in each case independently of one another denote hydrogen, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-3-alkyl, heterocyclyl, heterocyclyl-C1-3-alkyl, aryl, aryl-C1-3-alkyl, heteroaryl or heteroaryl-C1-3-alkyl,
wherein the above mentioned groups may optionally be substituted independently of one another by one or more groups selected from among fluorine, chlorine, bromine, iodine, hydroxy, oxo, carboxy, formyl, cyano, nitro, C1-3-alkyl- and C1-3-alkoxy-,
the pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates and solvates thereof.

### Claim 2 (depends on 1)

Compounds according to claim 1, characterised in that
A denotes phenyl or a 5- or 6-membered aromatic heteroaryl group which contains 1, 2 or 3 heteroatoms selected from N, O and S.

### Claim 3 (depends on 1)

Compounds according to claim 1, characterised in that the group
is selected from among

### Claim 4 (depends on 1)

Compounds according to claim 1, characterised in that
A denotes phenyl, thienyl, thiazolyl, pyrazolyl or pyridyl.

### Claim 5 (depends on 1)

Compounds according to claim 1, characterised in that
L in each case independently of one another denote hydrogen, fluorine, chlorine, bromine, iodine, hydroxy, carboxy, cyano, nitro, F3C, HF2C, FH2C, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-3-alkyl, aryl, aryl-C1-3-alkyl, heterocyclyl, heterocyclyl-C1-3-alkyl, heteroaryl, heteroaryl-C1-3-alkyl, R13—O, R13—O—C1-3-alkyl, (R12)2N, (R12)2N—CO, R12—CO—(R12)N, (R12)2N—CO—(R12)N, (R12)2N—SO2, R12—SO2—(R12)N or C1-3-alkyl-SO2,
wherein the above mentioned groups may optionally be substituted independently of one another by one or more groups selected from among fluorine, chlorine, bromine, hydroxy, oxo, carboxy, cyano, nitro, F3C, HF2C, FH2C, hydroxy-C1-3-alkyl, C1-3-alkyl, C1-3-alkoxy, (R12)2N, (R12)2N—C1-3-alkyl- and (R12)2N—CO—, and
i denotes 0, 1 or 2.

### Claim 6 (depends on 1)

Compounds according to claim 1, characterised in that
L in each case independently of one another denote hydrogen, fluorine, chlorine, bromine, cyano, hydroxy, C1-6-alkyl, C1-6-alkoxy, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-3-alkyl, phenyl, (R12)2N, (R12)2N—CO, R12—CO—(R12)N, (R12)2N—CO—(R12)N, R12—SO2—(R12)N or (R12)2N—SO2,
wherein the above mentioned groups may optionally be substituted by one or more fluorine atoms, and
i denotes 0, 1 or 2.

### Claim 7 (depends on 1)

Compounds according to claim 1, characterised in that
L in each case independently of one another denote hydrogen, fluorine, chlorine, bromine, hydroxy, C1-4-alkyl or C1-4-alkoxy,
wherein the above mentioned groups may optionally be substituted by one or more fluorine atoms, and
i denotes 0, 1 or 2.

### Claim 8 (depends on 1)

Compounds according to claim 1, characterised in that
B denotes a C1-4-alkylene bridge,
wherein the C1-4-alkylene bridge may optionally be substituted independently of one another by one or more groups selected from among fluorine, hydroxy, carboxy, cyano, nitro, F3C, HF2C, FH2C, C1-4-alkyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-3-alkyl, heterocyclyl, heterocyclyl-C1-3-alkyl, aryl, aryl-C1-3-alkyl, heteroaryl, heteroaryl-C1-3-alkyl, R13—O, (R12)2N—SO2— and (R12)2N— may be substituted, and
wherein two C1-4-alkyl groups bound to the same carbon atom of the C1-4-alkylene bridge may be joined together, forming a C3-7-cycloalkyl group, and
wherein the above mentioned groups and the C3-7-cycloalkyl group formed from the C1-4-alkyl groups may optionally be substituted independently of one another by one or more groups selected from among fluorine, chlorine, bromine, hydroxy, carboxy, cyano, F3C, C1-3-alkyl, C1-3-alkoxy and R13—O—C1-3-alkyl.

### Claim 9 (depends on 1)

Compounds according to claim 1, characterised in that
B denotes a C1-4-alkylene bridge,
wherein the C1-4-alkylene bridge may optionally be substituted independently of one another by one or more groups selected from among fluorine, C1-4-alkyl, phenyl or benzyl, and
wherein two C1-4-alkyl groups bound to the same carbon atom of the C1-4-alkylene bridge may be joined together, forming a C3-6-cycloalkyl group, and
wherein the above mentioned groups and the C3-6-cycloalkyl group formed from the C1-4-alkyl groups may optionally be substituted independently of one another by one or more groups selected from among fluorine, hydroxy and C1-3-alkoxy.

### Claim 10 (depends on 1)

Compounds according to claim 1, characterised in that
B denotes a C1-2-alkylene bridge,
wherein the C1-2-alkylene bridge may optionally be substituted by one or more C1-4-alkyl groups, and
wherein two C1-4-alkyl groups bound to the same carbon atom of the C1-2-alkylene bridge may be joined together forming a cyclopropyl group, and
wherein one or more hydrogen atoms of the above mentioned C1-2-alkylene bridge and/or of the C1-4-alkyl groups and/or the cyclopropyl group formed therefrom may optionally be replaced by one or more fluorine atoms.

### Claim 11 (depends on 1)

Compounds according to claim 1, characterised in that
B is selected from among
wherein one or more hydrogen atoms may optionally be replaced by fluorine.

### Claim 12 (depends on 1)

Compounds according to claim 1, characterised in that the partial formula (II)
is selected from among

### Claim 13 (depends on 1)

Compounds according to claim 1, characterised in that
R1 denotes hydrogen, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-3-alkyl, heterocyclyl, heterocyclyl-C1-3-alkyl, aryl, aryl-C1-3-alkyl, heteroaryl or heteroaryl-C1-3-alkyl,
wherein the above mentioned groups may optionally be substituted independently of one another by one or more groups selected from among fluorine, chlorine, bromine, hydroxy, carboxy, cyano, nitro, F3C, C1-3-alkyl, C1-3-alkoxy- and hydroxy-C1-3-alkyl.

### Claim 14 (depends on 1)

Compounds according to claim 1, characterised in that
R1 denotes hydrogen, C1-4-alkyl, C3-4-alkenyl, C3-6-cycloalkyl, C3-6-cycloalkyl-C1-3-alkyl,
wherein the above mentioned groups may optionally be substituted independently of one another by one or more groups selected from among fluorine, hydroxy and C1-3-alkoxy.

### Claim 15 (depends on 1)

Compounds according to claim 1, characterised in that
R2 denotes C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C1-6-alkoxy-C1-3-alkyl, C1-6-alkyl-S—C1-3-alkyl, C3-7-cycloalkyl, heterocyclyl, heterocyclyl-C1-3-alkyl, aryl, aryl-C1-3-alkyl, heteroaryl or heteroaryl-C1-3-alkyl,
wherein the above mentioned groups may optionally be substituted independently of one another by one or more groups selected from among fluorine, chlorine, bromine, iodine, F3C, HF2C, FH2C, hydroxy, carboxy, cyano, nitro, C1-3-alkyl, (R12)2N, (R12)2N—SO2, R12—CO—(R12)N, R12—SO2(R12)N, (R(R12)2N—CO, R13—O— and R13—O—C1-3-alkyl.

### Claim 16 (depends on 1)

Compounds according to claim 1, characterised in that
R2 denotes C1-6-alkyl, C2-6-alkynyl, C3-6-cycloalkyl-C1-3-alkyl, heterocyclyl-C1-3alkyl, phenyl, phenyl-C1-3-alkyl, heteroaryl or heteroaryl-C1-3-alkyl,
wherein by the above mentioned heteroaryl groups are meant 5- or 6-membered aromatic heteroaryl groups which contain 1, 2 or 3 heteroatoms selected from among N, O and S and
wherein the above mentioned groups may optionally be substituted independently of one another by one or more groups selected from among fluorine, chlorine, bromine, iodine, cyano, hydroxy, C1-3-alkyl, F3C, HF2C, FH2C, H2N— and C1-3-alkoxy.

### Claim 17 (depends on 1)

Compounds according to claim 1, characterised in that
R2 denotes n-propyl, n-butyl, 2-propynyl, 2-butynyl, cyclohexylmethyl, cyclopentylmethyl, phenylmethyl, 2-phenylethyl, pyridylmethyl, furanylmethyl, thienylmethyl or thiazolylmethyl,
wherein the above mentioned propyl, butyl, propynyl, butynyl, cyclohexylmethyl and cyclopentylmethyl groups may optionally be substituted by one or more fluorine atoms and the phenylmethyl, 2-phenylethyl, pyridylmethyl, furanylmethyl, thienylmethyl or thiazolylmethyl groups may optionally be substituted independently of one another by one or more groups selected from among fluorine, chlorine, bromine, methyl, F3C, HF2C, FH2C— and H2N.

### Claim 18 (depends on 1)

Compounds according to claim 1, characterised in that
R3 denotes hydrogen, fluorine, methyl, F3C, HF2C or FH2C— and
R4 denotes hydrogen or fluorine.

### Claim 19 (depends on 1)

Compounds according to claim 1, characterised in that
R3 denotes hydrogen and
R4 denotes hydrogen.

### Claim 20 (depends on 1)

Compounds according to claim 1, characterised in that
R5 denotes hydrogen, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-3-alkyl, C3-7-cycloalkenyl, C3-7-cycloalkenyl-C1-3-alkyl, heterocyclyl, heterocyclyl-C1-3-alkyl, aryl, aryl-C1-3-alkyl, heteroaryl, or heteroaryl-C1-3-alkyl,
wherein the above mentioned groups may optionally be substituted independently of one another by one or more groups selected from among fluorine, chlorine, bromine, iodine, hydroxy, carboxy, cyano, nitro, C1-3-alkyl, C1-3-alkoxy, C1-3-alkyl-S, aryl, heteroaryl, heteroaryl-C1-3-alkyl, aryl-C1-3-alkyl, (R12)2N—SO2, (R12)2N, (R12)2N—C1-3-alkyl- and (R12)2N—CO.

### Claim 21 (depends on 1)

Compounds according to claim 1, characterised in that
R5 denotes C1-6-alkyl, cyclopropyl, C3-6-cycloalkyl-C1-3-alkyl or phenyl-C1-3-alkyl, wherein the above mentioned groups may optionally be substituted independently of one another by one or more groups selected from among fluorine, chlorine, bromine, iodine, cyano, hydroxy, carboxy, C1-4-alkyl, C1-4-alkoxy- and (R12)2N—.

### Claim 22 (depends on 1)

Compounds according to claim 1, characterised in that
R5 denotes C1-4-alkyl or cyclopropyl,
wherein one or more hydrogen atoms of the above mentioned groups may optionally be replaced by fluorine atoms.

### Claim 23 (depends on 1)

Compounds according to claim 1, characterised in that
R6 denotes C2-6-alkenyl, C2-6-alkynyl, C3-7-cycloalkenyl, C3-7-cycloalkenyl-C1-3-alkyl, heterocyclyl, heterocyclyl-C1-3-alkyl, (R12)2N-aryl, (R12)2N-aryl-C1-3-alkyl, heteroaryl or heteroaryl-C1-3-alkyl,
wherein the above mentioned groups may optionally be substituted independently of one another by one or more groups selected from among fluorine, chlorine, bromine, iodine, hydroxy, carboxy, cyano, nitro, C1-3-alkyl, C3-7-cycloalkyl, heterocyclyl, heterocyclyl-C1-3-alkyl, aryl, aryl-C1-3-alkyl, heteroaryl, heteroaryl-C1-3-alkyl, (R12)2N, (R12)2N—C1-3-alkyl, (R12)2N—CO, R12—CO—(R12)N, (R12)2N—CO—N(R12), (R12)2N—SO2, R12—SO2, R12—SO2—(R12)N, R13—O— and R12—O—C1-3-alkyl.

### Claim 24 (depends on 1)

Compounds according to claim 1, characterised in that
R6 denotes C2-6-alkenyl, C2-6-alkynyl, C3-6-cycloalkyl-C1-3-alkyl, heterocyclyl, heterocyclyl-C1-3-alkyl, (R12)2N-phenyl, (R12)2N-phenyl-C1-3-alkyl, heteroaryl or heteroaryl-C1-3-alkyl,
wherein by the above-mentioned heteroaryl groups are meant 5- or 6-membered aromatic heteroaryl groups which contain 1, 2 or 3 heteroatoms selected from among N, O and S and
wherein the above mentioned groups may optionally be substituted independently of one another by one or more groups selected from among fluorine, chlorine, bromine, carboxy, hydroxy, cyano, C1-3-alkyl, C1-3-alkoxy, C1-3-alkoxy-C1-3-alkyl, hydroxy-C1-3-alkyl, C3-5-cycloalkyl, heterocyclyl, heterocyclyl-C1-3-alkyl, aryl, (R12)2N, (R12)2N—C1-3-alkyl, (R12)2N—CO, (R12)2N—CO—N(R12), R12—CO—(R12)N— and (R12)2N—SO2—.

### Claim 25 (depends on 1)

Compounds according to claim 1, characterised in that
R6 denotes (R12)2N-phenyl-C1-3-alkyl or C3-6-cycloalkyl-C1-3-alkyl,
wherein the above mentioned groups may optionally be substituted independently of one another by one or more groups selected from among fluorine, hydroxy, cyano, C1-3-alkyl, C1-3-alkoxy, hydroxy-C1-3-alkyl, (R12)2N, (R12)2N—C1-3-alkyl, (R12)2N—CO—N(R12)— and (R12)2N—SO2—.

### Claim 26 (depends on 1)

Compounds according to claim 1, characterised in that
R6 denotes 4-aminobenzyl, cyclobutylmethyl, 2-cyclopropylethyl or cyclopropylmethyl,
wherein the above mentioned groups may optionally be substituted independently of one another by one or more groups selected from among fluorine and C1-3-alkyl, particularly preferably by methyl.

### Claim 27 (depends on 1)

Compounds according to claim 1, characterised in that
R7 denotes hydrogen or C1-4-alkyl,
while one or more hydrogen atoms of the C1-4-alkyl group may be replaced by fluorine.

### Claim 28 (depends on 1)

Compounds according to claim 1, characterised in that
R8 denotes hydrogen, fluorine, chlorine, bromine, cyano, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-3-alkyl, heterocyclyl, heterocyclyl-C1-3-alkyl, C3-7-cycloalkenyl, aryl, aryl-C1-3-alkyl, heteroaryl, heteroaryl-C1-3-alkyl, R13—O, R13—O—C1-3-alkyl, R10—SO2—(R11)N or R10—CO—(R11)N,
wherein the above mentioned groups may optionally be substituted independently of one another by one or more groups selected from among C1-6-alkyl, fluorine, chlorine, bromine, hydroxy, oxo, carboxy, cyano, nitro, C3-7-cycloalkyl, heterocyclyl, (R12)2N, (R12)2N—CO, R13—CO, R13—O—CO, R12—CO—(R12)N, (R12)2N—CO—(R12)N, (R12)2N—SO2, (R12)2N—SO2—(R12)N, R12—SO2, R13—O, C1-4-alkyl-S, F3C, HF2C, FH2C, F3C—O, HF2C—O, FH2C—O— and R12—SO2—(R12)N—, and
R9 in each case independently of one another denote hydrogen, fluorine, chlorine, bromine, methyl, F2HC, FH2C or F3C.

### Claim 29 (depends on 1)

Compounds according to claim 1, characterised in that
R8 denotes hydrogen, fluorine, chlorine, bromine, cyano, C1-4-alkyl, C1-4-alkoxy, C3-6-cycloalkyl, C3-6-cycloalkyl-oxy, C3-6-cycloalkyl-C1-3-alkoxy, phenyl, pyridyl, thienyl, furyl, R10—CO—(R11)N or R10—SO2—(R11)N,
wherein the above mentioned groups may optionally be substituted independently of one another by one or more groups selected from among fluorine, chlorine, bromine, carboxy, cyano, C1-3-alkyl, C1-3-alkoxy, C1-4-alkyl-S, R13—CO, R13—O—CO, R12—SO2, F3C, HF2C, FH2C, F3C—O, HF2C—O, FH2C—O— and (R12)2N—CO—, and
R9 in each case independently of one another denote hydrogen, fluorine, chlorine or bromine.

### Claim 30 (depends on 1)

Compounds according to claim 1, characterised in that
R8 denotes R10—SO2—(R11)N, R10—CO—(R11)N, cyanophenyl or cyanothienyl,
wherein the above mentioned cyanophenyl- and cyanothienyl groups may optionally be substituted independently of one another by one or more groups selected from among fluorine, chlorine, bromine, C1-4-alkyl, C1-4-alkoxy, F3C, HF2C, FH2C, F3C—O, HF2C—O—0 and FH2C—O—, and
R9 in each case independently of one another denote hydrogen, fluorine, chlorine or bromine.

### Claim 31 (depends on 1)

Compounds according to claim 1, characterised in that
R10 denotes C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-3-alkyl, C3-7-cycloalkenyl, C3-7-cycloalkenyl-C1-3-alkyl, heterocyclyl, heterocyclyl-C1-3-alkyl, aryl, aryl-C1-3-alkyl, heteroaryl, heteroaryl-C1-3-alkyl or (R12)2N,
wherein the above mentioned groups may optionally be substituted by one or more groups selected from among fluorine, chlorine, bromine, hydroxy, carboxy, cyano, nitro, C1-3-alkyl, heterocyclyl, heterocyclyl-C1-3-alkyl, C1-3-alkoxy, hydroxy-C1-3-alkyl, R12—CO(R12)N, R12—SO2(R12)N, (R12)2N, (R12)2N—C1-3-alkyl- and (R12)2N—CO—, and
R11 denotes hydrogen, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C3-7-cycloalkyl, C3-7-cycloalkyl, C1-3-alkyl, heterocyclyl, heterocyclyl-C1-3-alkyl, aryl, aryl-C1-3-alkyl, heteroaryl or heteroaryl-C1-3-alkyl,
wherein the above mentioned groups may optionally be substituted independently of one another by one or more groups selected from among fluorine, chlorine, bromine, hydroxy, cyano, C1-3-alkyl, C1-3-alkoxy, hydroxy-C1-3-alkyl, heterocyclyl, heterocyclyl-C1-3-alkyl, (R12)2N— and (R12)2N—C1-3-alkyl.

### Claim 32 (depends on 1)

Compounds according to claim 1, characterised in that
R10 denotes C1-6-alkyl, heterocyclyl, phenyl, phenyl-C1-3-alkyl, heteroaryl, heteroaryl-C1-3-alkyl or (R12)2N,
wherein by the above mentioned heteroaryl groups are meant 5- or 6-membered aromatic heteroaryl groups which contain 1, 2 or 3 heteroatoms selected from among N, O and S and
wherein the above mentioned groups may optionally be substituted independently of one another by one or more groups selected from among fluorine, chlorine, bromine, hydroxy, cyano, C1-3-alkyl, C1-3-alkoxy, heterocyclyl, heterocyclyl-C1-3-alkyl, hydroxy-C1-3-alkyl, (R12)2N— and (R12)2N—C1-3-alkyl, and
R11 denotes hydrogen, C1-6-alkyl, C3-6-cycloalkyl, C3-6-cycloalkyl-C1-3-alkyl, heterocyclyl, heterocyclyl-C1-3-alkyl, phenyl, phenyl-C1-3-alkyl, heteroaryl or heteroaryl-C1-3-alkyl,
wherein by the above-mentioned heteroaryl groups are meant 5- or 6-membered aromatic heteroaryl groups which contain 1, 2 or 3 heteroatoms selected from among N, O and S, and
wherein the above mentioned groups may optionally be substituted independently of one another by one or more groups selected from among fluorine, chlorine, bromine, hydroxy, cyano, C1-3-alkyl, C1-3-alkoxy, hydroxy-C1-3-alkyl, heterocyclyl, heterocyclyl-C1-3-alkyl, (R12)2N— and (R12)2N—C1-3-alkyl.

### Claim 33 (depends on 1)

Compounds according to claim 1, characterised in that
R10 denotes C1-4-alkyl, morpholinyl, piperidinyl, 4-methylpiperidinyl, pyrrolidinyl, phenyl, 4-fluorophenyl, benzyl, pyridyl or (CH3)2N,
wherein the above mentioned groups may optionally be substituted independently of one another by one or more groups selected from among fluorine, chlorine and bromine,
R11 denotes hydrogen, methyl, HF2C, ethyl, phenyl or 4-fluorophenyl,
wherein the above mentioned groups may optionally be substituted independently of one another by one or more groups selected from among fluorine, chlorine and bromine.

### Claim 34 (depends on 1)

Compounds according to claim 1, characterised in that
R10 and R11 together form a C2-6-alkylene bridge, so that a heterocyclic ring is formed with the inclusion of the nitrogen atom linked to RH and the SO2— or CO— group linked to R10,
wherein one or two —CH2 groups of the C2-6-alkylene bridge may be replaced independently of one another by O, S, SO, SO2 or —N(R12)— such that in each case two O or S atoms or an O and an S atom are not directly connected to one another, and
wherein the C atoms of the above mentioned C2-6-alkylene bridge may optionally be substituted independently of one another by one or more groups selected from among fluorine, hydroxy, carboxy, F3C, C1-3-alkyl and C1-3-alkoxy.

### Claim 35 (depends on 1)

Compounds according to claim 1, characterised in that
R10 and R11 with the inclusion of the nitrogen atom bound to R11 and the SO2— or CO group bound to R10, together form a heterocyclic ring of formulae (IIa), (IIb), (IIc) or (IId)

### Claim 36 (depends on 1)

Compounds according to claim 1, characterised in that
R12 in each case independently of one another denotes hydrogen or a C1-6-alkyl group wherein one or more hydrogen atoms of the C1-6-alkyl group may be replaced by fluorine.

### Claim 37 (depends on 1)

Compounds according to claim 1, characterised in that
R13 in each case independently of one another denotes hydrogen or a C1-3-alkyl group, wherein one or more hydrogen atoms of the C1-3-alkyl group may be replaced by fluorine.

### Claim 38 (depends on 1)

Compounds according to claim 1 from among the formulae (Ia), (Ib), (Ic), (Id), (Ie), (If) or (Ig)
wherein
A, B, L, i, R1, R2, R3, R4, R5, R8, R9, R9, R10, R11, R12, R13, R12 and R13 have the meanings given in the preceding claims.

### Claim 39 (depends on 1)

Physiologically acceptable salts of the compounds according to claim 1.

### Claim 40 (depends on 1)

Use of a compound according to claim 1 as a medicament.

### Claim 41 (depends on 1)

Pharmaceutical composition containing a compound according to claim 1 optionally together with one or more inert carriers and/or diluents.

### Claim 42 (depends on 41)

Pharmaceutical composition according to claim 41, containing one or more medicinally effective active substances selected from among beta-secretase inhibitors, gamma-secretase inhibitors, amyloid aggregation inhibitors, directly or indirectly acting neuroprotective substances, antioxidants, Cox inhibitors, NSAIDs with additionally or only Aβ lowering properties; HMG-CoA reductase inhibitors, AMPA agonists; substances that modulate the concentration or release of neurotransmitters, substances that induce the secretion of growth hormone, CB-1 receptor antagonists or inverse agonists, antibiotics, PDE-IV inhibitors, PDE-IX inhibitors, GABAA inverse agonists, nicotine agonists, histamine H3 antagonists, 5 HT-4 agonists or partial agonists, 5HT-6 antagonists, a2-adrenoreceptor antagonists, muscarinic M1 agonists, muscarinic M2 antagonists, metabotropic glutamate-receptor 5 positive modulators.

### Claim 43 (depends on 41)

Pharmaceutical composition according to claim 41, containing one or more medicinally effective active substances selected from among Alzhemed, Vitamin E, ginkgolides, donepezil, rivastigmine, tacrine, galantamine, memantine, NS-2330, ibutamoren mesylate, capromorelin, minocycline and rifampicin.

### Claim 44 (depends on 1)

Use of at least one compound according to claim 1 as a β-secretase inhibitor.

### Claim 45 (depends on 1)

Use of at least one compound according to claim 1 or a pharmaceutical composition thereof for preparing a medicament which is suitable for the treatment or prevention of diseases or conditions that are associated with abnormal processing of Amyloid Precursor Protein (APP) or aggregation of Abeta peptide.

### Claim 46 (depends on 1)

Use of at least one compound according to claim 1 or a pharmaceutical composition thereof for preparing a medicament which is suitable for the treatment or prevention of diseases or conditions that can be influenced by inhibiting the β-secretase activity.

### Claim 47 (depends on 1)

Use of at least one compound according to claim 1 or a pharmaceutical composition thereof for preparing a medicament for the treatment or prevention of Alzheimer's disease (AD), MCI (“mild cognitive impairment”), trisomy 21 (Down's syndrome), cerebral amyloidangiopathy, degenerative dementias, hereditary cerebral haemorrhage with amyloidosis—Dutch type (HCHWA-D), Alzheimer's dementia with Lewy bodies, trauma, stroke, pancreatitis, inclusion body myositis (IBM), as well as peripheral amyloidoses, diabetes or arteriosclerosis.

### Claim 48 (depends on 1)

Use of at least one compound according to claim 1 or a pharmaceutical composition thereof for preparing a medicament for the treatment or prevention of Alzheimer's disease (AD).

### Claim 49 (depends on 1)

Method of inhibiting β-secretase activity, characterised in that β-secretase is brought into contact with an inhibitory amount of a compound according to claim 1.
